Resurrect Bio announced the $8.1 million initial close of its Series A funding round, led by Corteva through its Corteva Catalyst platform. Additional participants in the round include Calculus Capital, Pymwymic, UKI2S, SynBioVen, and AgFunder.
The London-based biotechnology company is focused on equipping crops with genetic defenses against disease. The Series A funding marks a key milestone as the company advances sustainable crop protection solutions to address global food security challenges.
Proceeds from the round will be used to accelerate Resurrect Bio’s high-throughput trait discovery platform and to advance multiple disease-resistance products toward commercial partnerships. The company said its approach is designed to bring solutions to farmers faster than conventional breeding methods.
Resurrect Bio’s proprietary platform integrates its FloraFold AI computational biology technology with high-throughput plant screening to identify and “resurrect” disease resistance genes that have been suppressed by pathogens. The process involves making small edits to native plant genes, restoring crops’ ability to defend themselves against disease. The company believes this gene-editing-based strategy offers a sustainable alternative to chemical crop protection while protecting yields.
Corteva, through its Corteva Catalyst platform, partners with early-stage innovators to accelerate the development of disruptive agricultural technologies that help farmers sustainably increase food and feed production.
Resurrect Bio was spun out of The Sainsbury Laboratory in Norwich and was founded by Prof. Sophien Kamoun, Prof. Tolga Bozkurt, and Dr. Cian Duggan.
KEY QUOTES
“We’re thrilled to have secured this investment from such a distinguished group of partners who share our vision of delivering durable disease resistance to farmers. With Corteva’s leadership and the support of Calculus Capital, Pymwymic and our existing investors, we’re now positioned to scale our platform and deliver multiple resistance traits to the seed industry.”
Dr. Cian Duggan, CEO, Resurrect Bio
“Our collaboration with Resurrect Bio signals another step in our journey to discover new technologies that provide farmers more sustainable crop protection solutions. We’re excited to work with Resurrect Bio and explore the next generation of gene editing capabilities to further unlock the potential of our world-class germplasm.”
Tom Greene, Senior Director And Global Leader For Corteva Catalyst, Corteva
